Work

Overcoming translational and manufacturing barriers of CAR-T cell therapy in the Brazilian landscape

Year: 2026
Type: review
Abstract: Chimeric antigen receptor (CAR) T cell therapy represents an advancement in the treatment of hematologic malignancies, offering remissions in relapsed or refractory disease. However, its global implementation is limited by high production costs, logistical complexity, and the need for specialized facilities that comply with biosafety and regulatory standards. In Brazil, all CAR-T products are imported, leading to high costs and delays in patient access. To overcome these barriers, academic institutions have established local CAR-T manufacturing platforms. This review provides an overview of the scientific, technical, and regulatory aspects of academic CAR-T development in Brazil, highlighting key advances and challenges. We discuss cell sources, gene-transfer systems, manufacturing strategies, quality control (QC), and regulatory frameworks. Efforts from institutions such as Hospital Israelita Albert Einstein, University of São Paulo (USP), Butantan Institute, National Cancer Institute (INCA), and Oswaldo Cruz Foundation (Fiocruz) demonstrate complementary approaches. These initiatives underscore the feasibility of developing CAR-T therapies in low- and middle-income countries through innovation, technology transfer, and financing. Finally, we address the integration of CAR-T therapy into the Brazilian public health system, emphasizing workforce training, clinical logistics, and cost-effectiveness to ensure access. Overall, the Brazilian experience illustrates how academic collaboration can translate research into clinical application.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,900
OpenAlex ID: W7221761872
FWCI:
Cites: 50
Cited by:
Related to: 10